TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.7 CNY | +0.27% |
|
+1.38% | -2.23% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.55 for the current year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.23% | 1.63B | - | ||
| +26.08% | 681B | C+ | ||
| +21.85% | 556B | B | ||
| -4.77% | 361B | C+ | ||
| +16.97% | 325B | B- | ||
| +5.69% | 285B | C+ | ||
| +13.68% | 235B | B+ | ||
| +3.65% | 199B | B- | ||
| -11.12% | 189B | A+ | ||
| -3.40% | 157B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600211 Stock
- Ratings Tibet Rhodiola Pharmaceutical Holding Co.
